Skip to content
Screener

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$22.32B+28.0%
Gilead Sciences logo
Gilead SciencesGILD
$11.83B-39.9%
Precigen logo
PrecigenPGEN
$20.24M+244%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$1.81B-0.8%
Sana Biotechnology logo
Sana BiotechnologySANA
$119.24M-43.0%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$347.5M+133%

Other financials

Income statement

See full
Revenue-
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$693.76M+205%
Enterprise value$734.21M+192%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-034585
Line itemMarch 31,2026December 31,2025
Stockholders’ equity:
Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares were issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.001 par value: 400,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 244,816,413 and 229,413,523 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively245229
Additional paid-in capital2,332,1292,302,753
Accumulated deficit(2,053,316)(2,010,709)
Accumulated other comprehensive income (loss)(183)269
Total stockholders’ equity278,875292,542
Total liabilities and stockholders’ equity$395,958$415,905

Item 1. Financial Statements - Unaudited

FAQ

What is Allogene Therapeutics's total equity?
Allogene Therapeutics (ALLO) reported total equity of $278.88M in Q1 2026.
How has Allogene Therapeutics's total equity changed year-over-year?
Allogene Therapeutics's total equity decreased by 27.6% year-over-year, from $385.39M to $278.88M.
What is the long-term trend for Allogene Therapeutics's total equity?
Over 5 years (2020 to 2025), Allogene Therapeutics's total equity has grown at a -22.0% compound annual growth rate (CAGR), from $1.01B to $292.54M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Allogene Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude